Alectinib

Generic Name
Alectinib
Brand Names
Alecensa, Alecensaro
Drug Type
Small Molecule
Chemical Formula
C30H34N4O2
CAS Number
1256580-46-7
Unique Ingredient Identifier
LIJ4CT1Z3Y
Background

Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...

Indication

Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...

Associated Conditions
Refractory, metastatic Non small cell lung cancer
Associated Therapies
-
Clinical Trials
Related News

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

First Posted Date
2020-11-25
Last Posted Date
2023-08-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1
Registration Number
NCT04644315
Locations
🇺🇸

Science 37-Cannon; Dept 002-Cannon, Culver City, California, United States

🇺🇸

Science 37-Basem; Dept 004- Basem, Culver City, California, United States

🇺🇸

Science 37, Inc, Culver City, California, United States

and more 4 locations

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

First Posted Date
2020-11-17
Last Posted Date
2024-03-07
Lead Sponsor
Genentech, Inc.
Target Recruit Count
252
Registration Number
NCT04632992
Locations
🇺🇸

Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States

🇺🇸

Ascension St. John Hospital, Detroit, Michigan, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 42 locations

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

First Posted Date
2020-10-19
Last Posted Date
2024-11-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
920
Registration Number
NCT04589845
Locations
🇺🇸

Southern Cancer Center, Daphne, Alabama, United States

🇺🇸

Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States

🇺🇸

Hoag Memorial Hospital, Newport Beach, California, United States

and more 171 locations

CRAFT: the NCT-PMO-1602 Phase II Trial

First Posted Date
2020-09-16
Last Posted Date
2024-12-11
Lead Sponsor
German Cancer Research Center
Target Recruit Count
175
Registration Number
NCT04551521
Locations
🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany

🇩🇪

Universitätsklinikum Freiburg, Freiburg, Germany

and more 5 locations

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Completed
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Drug: Alectinib
First Posted Date
2020-04-17
Last Posted Date
2023-03-27
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT04351334
Locations
🇺🇸

Pfizer Inc, New York, New York, United States

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

First Posted Date
2020-04-10
Last Posted Date
2022-10-26
Lead Sponsor
Ulrik Lassen
Target Recruit Count
300
Registration Number
NCT04341181
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

and more 4 locations

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

First Posted Date
2020-03-10
Last Posted Date
2024-05-01
Lead Sponsor
Genentech, Inc.
Target Recruit Count
125
Registration Number
NCT04302025
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

UCLA Hematology Oncology, Los Angeles, California, United States

🇺🇸

Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

and more 31 locations

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.

First Posted Date
2019-10-04
Last Posted Date
2024-12-12
Lead Sponsor
Centre Leon Berard
Target Recruit Count
455
Registration Number
NCT04116541
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Institut Paoli Calmettes, Marseille, France

and more 5 locations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

First Posted Date
2019-05-10
Last Posted Date
2024-07-17
Lead Sponsor
AstraZeneca
Target Recruit Count
248
Registration Number
NCT03944772
Locations
🇸🇪

Research Site, Stockholm, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy